Biocartis

Mechelen, Belgium Founded: 2007 • Age: 19 yrs
Molecular assays for disease detection are developed using proprietary technology.
Request Access

About Biocartis

Biocartis is a company based in Mechelen (Belgium) founded in 2007.. Biocartis has raised $305.3 million across 18 funding rounds from investors including Philips, Johnson & Johnson and KBC Bank & Verzekering. Biocartis has completed 1 acquisition, including Pronota. Biocartis offers products and services including Idylla Platform, Oncology Tests, and Research Assays. Biocartis operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.

  • Headquarter Mechelen, Belgium
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biocartis Nv
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $305.3 M (USD)

    in 18 rounds

  • Latest Funding Round
  • Investors
    Philips

    & 18 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Biocartis

Biocartis offers a comprehensive portfolio of products and services, including Idylla Platform, Oncology Tests, and Research Assays. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Automated system for rapid molecular testing in oncology labs

Tests for detecting mutations in cancer biomarkers quickly

Assays for exploring new biomarkers in research settings

People of Biocartis
Headcount 200-500
Employee Profiles 27
Board Members and Advisors 4
Employee Profiles
People
Anthony Green
Executive Vice President, Corporate & Business Development
People
Evelien Rondelez
Design And Development Support Manager
People
Sarah Saunders
Senior Product Specialist UK And Ireland
People
Peter Mousa
Export Business Manager

Unlock access to complete

Board Members and Advisors
people
Ann-Christine Sundell
Director
people
Luc Gijsens
Director
people
Christian Reinaudo
Lead Independent Director
people
Herman Verrelst
Chairman

Unlock access to complete

Funding Insights of Biocartis

Biocartis has successfully raised a total of $305.3M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 18
  • Last Round
  • First Round

    (15 Oct 2009)

  • Investors Count 19
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2022 Amount Post-IPO - Biocartis Valuation

investors

May, 2021 Amount Grant - Biocartis Valuation

investors

Dec, 2020 Amount Post-IPO - Biocartis Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Biocartis

Biocartis has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Philips, Johnson & Johnson and KBC Bank & Verzekering. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity is directed toward private and public companies.
Founded Year Domain Location
Venture capital firm backed by Johnson & Johnson
Founded Year Domain Location
Private debt funds are managed across multiple sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Biocartis

Biocartis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pronota. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Diagnostics for heart failure, pre-eclampsia, and sepsis are provided.
2004
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Biocartis

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biocartis Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Biocartis

Biocartis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Health risks are identified through online genetic and diagnostic testing.
domain founded_year HQ Location
Adhesive patch biopsies for skin cancer detection are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Biocartis

Frequently Asked Questions about Biocartis

When was Biocartis founded?

Biocartis was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is Biocartis located?

Biocartis is headquartered in Mechelen, Belgium. It is registered at Mechelen, Antwerp, Belgium.

Is Biocartis a funded company?

Biocartis is a funded company, having raised a total of $305.3M across 18 funding rounds to date. The company's 1st funding round was a Post-IPO of $181.8M, raised on Oct 15, 2009.

What does Biocartis do?

Biocartis was founded in 2007 in Mechelen, Belgium, within the molecular diagnostics sector. Proprietary micro-technology platforms are utilized for integrated molecular and immunodiagnostics. Multiplexed detection, quantification, and amplification of bio-analytes such as proteins, nucleic acids, and small molecules are enabled. Analysis of biomolecules linked to disease risk factors, early detection, staging, treatment selection, and monitoring is supported across various applications.

Who are the top competitors of Biocartis?

Biocartis's top competitors include Guardant Health, Foundation Medicine and Natera.

What products or services does Biocartis offer?

Biocartis offers Idylla Platform, Oncology Tests, and Research Assays.

How many acquisitions has Biocartis made?

Biocartis has made 1 acquisition, including Pronota.

Who are Biocartis's investors?

Biocartis has 19 investors. Key investors include Philips, Johnson & Johnson, KBC Bank & Verzekering, Debiopharm, and PMV.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available